Sensei Biotherapeutics is developing Solnerstotug, a drug designed to target the VISTA checkpoint for cancer patients.
1 report, 1 independent
Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sensei Biotherapeutics is developing Solnerstotug, a drug designed to target the VISTA checkpoint for cancer patients.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AmeriCorps VISTA
National service program to alleviate poverty
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireSensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the s